HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis.

AbstractOBJECTIVES:
To conduct a comprehensive quantitative proteomics analysis of novel serum protein biomarkers based on synovitis status associated with matrix metalloproteinase-3 (MMP-3) and to determine the clinical significance of these biomarkers in rheumatoid arthritis (RA).
METHODS:
Patients with untreated RA (n=28), primary Sjogren's syndrome (pSS) (n=30), and healthy controls (HCs) (n=30) were enrolled for the screening assay. A total of 1128 serum proteins were analyzed using the SOMAscan™ assay. Serum levels of MMP-3 and interleukin (IL)-16 were measured using a latex turbidimetric immunoassay and ELISA at baseline and 12weeks after treatment with methotrexate (MTX) for MTX-naïve RA patients (n=28) or with the biologics tocilizumab (TCZ) (n=7), abatacept (ABT) (n=11) or infliximab (n=22) for MTX-inadequate response (IR) RA patients. Correlation analysis was conducted using Spearman's rank correlation method.
RESULTS:
Proteomics showed that serum IL-16 levels were most positively correlated with those of MMP-3 (ρ=0.51, p<0.01) and were significantly increased in patients with untreated active RA compared to HCs (p<0.01) or those with pSS (p<0.01). IL-16 levels decreased following treatment in both the MTX-naïve and MTX-IR groups. Regarding clinical response, fluctuations in IL-16 levels were positively associated with changes in clinical indicators, particularly the Clinical Disease Activity Index (ρ=0.89, p<0.01) in the TCZ and ABT-treated group. However, no similar correlation was noted in MMP-3 and acute phase reactants in any groups.
CONCLUSIONS:
IL-16 was a more effective clinical parameter than MMP-3, C-reactive protein, or erythrocyte sedimentation rate in both MTX-naive and MTX-IR RA patients. IL-16 might be a useful biomarker for evaluating clinical response in RA patients.
AuthorsAtsuko Murota, Katsuya Suzuki, Yoshiaki Kassai, Takahiro Miyazaki, Rimpei Morita, Yasushi Kondo, Masaru Takeshita, Yasuo Niki, Akihiko Yoshimura, Tsutomu Takeuchi
JournalCytokine (Cytokine) Vol. 78 Pg. 87-93 (Feb 2016) ISSN: 1096-0023 [Electronic] England
PMID26700586 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 Elsevier Ltd. All rights reserved.
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Biomarkers
  • Blood Proteins
  • Interleukin-16
  • Abatacept
  • Infliximab
  • MMP3 protein, human
  • Matrix Metalloproteinase 3
  • tocilizumab
  • Methotrexate
Topics
  • Abatacept (therapeutic use)
  • Adult
  • Aged
  • Antibodies, Monoclonal, Humanized (therapeutic use)
  • Antirheumatic Agents (therapeutic use)
  • Arthritis, Rheumatoid (blood, drug therapy)
  • Biomarkers (blood)
  • Blood Proteins (analysis, immunology)
  • Blood Sedimentation
  • Female
  • Humans
  • Infliximab (therapeutic use)
  • Interleukin-16 (blood)
  • Male
  • Matrix Metalloproteinase 3 (blood)
  • Methotrexate (therapeutic use)
  • Middle Aged
  • Proteomics
  • Statistics as Topic
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: